C3a C-Terminal Fragment, Amide

Amidated LGLARSD is a terminally modified C3a-derived peptide used for structure-activity analysis of complement receptor signaling. Amidation makes it chemically distinct from the corresponding free-acid fragment.

• complement biology
• inflammation and innate immunity
• receptor structure-activity studies
• immune signaling research

Exact residue boundaries and terminal modifications define product identity. Complement fragments can differ substantially in receptor potency from the intact anaphylatoxin.

1. Selected peer-reviewed publication